From off-label prescribing towards a new FDA

Originally published in Medical Hypotheses

Once a drug has been FDA-permitted for some use it can be prescribed for any use. New uses for old drugs are often discovered so a significant fraction of all prescriptions are for uses which were not tested in the FDA permitting process.

Once a drug has been FDA-permitted for some use it can be prescribed for any use. New uses for old drugs are often discovered so a significant fraction of all prescriptions are for uses which were not tested in the FDA permitting process. The prevalence of ‘off-label’ prescribing has generated concern that prescribing is not scientifically sound or in the patient interest. A better understanding and appreciation of the off-label system suggests that additional FDA regulation is not warranted but that reform of the FDA towards a Consumer Reports model may substantially benefit patients.

Find the article at Science Direct.

To speak with a scholar or learn more on this topic, visit our contact page.

Mercatus AI Assistant
Ask questions about this research.
GPT Logo
Mercatus AI Research Assistant
Ask questions about this research. Mercatus Chatbot AI More Details
Suggested Prompts:
Ask us anything. We use OpenAI's ChatGPT 4o base model to answer any question about Mercatus research.